A Snapshot at Pfizer’s Pipeline Progress
November 8, 2024Pfizer’s pipeline represents hope and optimism for patients and caregivers worldwide.
As a leading global biopharmaceutical company, Pfizer continues to innovate across multiple therapeutic areas, advancing its product pipeline with a focus on treating and preventing some of the world’s most challenging diseases. To date, Pfizer has reached billions of patients with its medicines and vaccines.
The first part of 2024 was noteworthy for Pfizer, marked by significant progress in clinical development, several regulatory approvals, and notable advancements. This progress demonstrates Pfizer’s steadfast commitment to delivering breakthroughs that make a difference.
Innovation and scientific leadership
Pfizer’s research and development (R&D) primarily focuses on these therapeutic areas: anti-infectives, inflammation and immunology, internal medicine, oncology, and vaccines.
Pfizer is working to deliver potential groundbreaking treatments and vaccines with advanced-stage development programs across all main therapeutic areas.
Robust pipeline featuring a total of 113 potential products or indications as of July 30, 2024 – including 65 new molecular entities and 48 additional indications.
A total of 17 programs advanced phases of development or are new in the first part of 2024 (as of July 30, 2024). A few highlights:
Oncology
We have advanced our oncology pipeline in the first part of 2024 with new Phase 3 studies for the treatment of advanced multiple myeloma, non‑small cell lung cancer and metastatic breast cancer. With over 50 clinical programs underway, Pfizer is well positioned to fulfill its 2030 oncology goal of delivering potentially 8 or more blockbuster medicines.
Vaccines
Our work continues in developing safe and effective vaccines to prevent infections and diseases. We have moved forward a late-stage clinical study to expand the patient population at increased risk for respiratory syncytial virus (RSV) disease as well as advanced a next-generation pneumococcal vaccine candidate into mid-stage development.
Obesity
Pfizer is working across the weight management continuum, of which obesity is a key area of focus for research. In July, we announced our plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of our preferred once-daily modified release formulation of our oral glucagon-like peptide-1 receptor agonist candidate for obesity.
Notably, in the first part of 2024, Pfizer secured seven regulatory approvals across the United States and Europe
Regulatory approvals include products to treat moderately to severely active ulcerative colitis; prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae; recurrent or metastatic cervical cancer with disease progression on or after chemotherapy; moderate to severe hemophilia B in certain adult patients; and more.
Pfizer is investing to deliver the next wave of pipeline innovation
The company continues to invest in next-generation science and technology to invent tomorrow’s innovative medicines and vaccines. In the first six months of 2024, Pfizer reinvested $5.2 billion in internal R&D projects.
Pfizer is on an exciting trajectory that builds on its legacy of discovering, developing, and delivering breakthroughs that have changed patients’ lives since 1849. With numerous investigational medicines and vaccines in late-stage development and several new entries into early phases, Pfizer remains at the forefront of pharmaceutical innovation.
Want to learn more?
Check out this guide to reading Pfizer’s product pipeline and Pfizer’s potential breakthroughs in the making.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.